StreetInsider.com News Articles

Cosmos Health appoints AI drug discovery expert to advisory board

Tue, 24 Feb 2026 12:30:19 -0500

Cosmos Health Inc. (NASDAQ: COSM) appointed Dr. Dimitrios Iliopoulos to its advisory board to support the company's biotechnology initiatives focused on AI-driven drug discovery and clinical-stage therapeutic development, according to a company statement.

Dr. Iliopoulos serves as co-founder and CEO of Athos Therapeutics Inc., an AI software and clinical-stage biotechnology company developing precision therapeutics for autoimmune diseases. Athos developed AthosOmics.AI, a proprietary AI-driven drug development platform that led to the discovery of ATH-063, an AI-derived small molecule currently in Phase 2 clinical trials for ulcerative colitis patients.

The appointee previously held academic positions at Harvard Medical School as an assistant professor of

Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board

Tue, 24 Feb 2026 12:30:00 -0500

CHICAGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the appointment of Dr. Dimitrios Iliopoulos to its Advisory Board, where he will support the Company’s biotechnology initiatives, with a focus on AI-driven drug discovery and clinical-stage therapeutic development.

Dr. Iliopoulos is a world-renowned expert in artificial intelligence, drug discovery, and drug development. He currently serves as Co-Founder and CEO of Athos Therapeutics Inc., an AI software and clinical-stage biotechnology company focused on developing precision therapeutics

Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board

Tue, 24 Feb 2026 12:30:00 -0500

Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board

Tue, 24 Feb 2026 12:30:00 -0500

Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board

Tue, 24 Feb 2026 12:30:00 -0500

Cosmos Health Highlights Approximately $15 Million Fair Market Value of Real Estate Assets, Exceeding Current Market Capitalization; Evaluates Monetization Options to Address Significant Discount to B

Thu, 19 Feb 2026 11:30:00 -0500

CHICAGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today highlighted the intrinsic value of its wholly owned real estate portfolio and announced that it is evaluating strategic monetization options to unlock shareholder value.

Based on independent valuation reports, recent market data, and comparable transactions, management estimates the combined fair market value of the Company’s Cana Laboratories (“Cana”) manufacturing facility and CosmoFarm logistics center at approximately $15 million. This estimate reflects the value of the land and

Cosmos Health Highlights Approximately $15 Million Fair Market Value of Real Estate Assets, Exceeding Current Market Capitalization; Evaluates Monetization Options to Address Significant Discount to B

Thu, 19 Feb 2026 11:30:00 -0500

Cosmos Health Highlights Approximately $15 Million Fair Market Value of Real Estate Assets, Exceeding Current Market Capitalization; Evaluates Monetization Options to Address Significant Discount to B

Thu, 19 Feb 2026 11:30:00 -0500

Cosmos Health Highlights Approximately $15 Million Fair Market Value of Real Estate Assets, Exceeding Current Market Capitalization; Evaluates Monetization Options to Address Significant Discount to B

Thu, 19 Feb 2026 11:30:00 -0500

Cosmos Health expands C-Scrub to Superdrug stores across UK

Wed, 18 Feb 2026 13:45:27 -0500

Cosmos Health Inc. (NASDAQ: COSM) announced that its antimicrobial skin cleanser C-Scrub is now available through Superdrug, the UK's second-largest beauty and health retailer.

The Chicago-based healthcare company said C-Scrub Wash Chlorhexidine 4% can be purchased through Superdrug's retail network, which operates more than 830 stores across the UK and Republic of Ireland. The retailer also maintains over 200 in-store pharmacies and operates an online e-commerce platform.

C-Scrub is described as an antiseptic wash designed to reduce bacteria and help prevent infection. The product contains chlorhexidine, a disinfectant commonly used in medical settings.

"Our entry into Superdrug further reinforces the growing retail momentum

Cosmos Health expands C-Scrub to Superdrug stores across UK

Wed, 18 Feb 2026 13:45:27 -0500

Cosmos Health Inc. (NASDAQ: COSM) announced that its antimicrobial skin cleanser C-Scrub is now available through Superdrug, the UK's second-largest beauty and health retailer.

C-Scrub is described as an antiseptic wash designed to reduce bacteria and help prevent infection. The product contains chlorhexidine, a disinfectant commonly used in medical settings.

"Our entry into Superdrug further reinforces the growing retail momentum

Cosmos Health Continues UK Retail Expansion for C-Scrub; Now Available at Superdrug, the UK’s Second-Largest Beauty and Health Retailer

Wed, 18 Feb 2026 13:45:00 -0500

CHICAGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced continued expansion of its United Kingdom (UK) retail footprint as its antimicrobial skin cleanser, C-Scrub Wash Chlorhexidine 4% (“C-Scrub”), is now available through Superdrug, the UK’s second-largest beauty and health retailer.